Literature DB >> 29807450

Local tumor progression after ultrasound-guided percutaneous microwave ablation of stage T1a renal cell carcinoma: risk factors analysis of 171 tumors.

Guoliang Hao1, Yanan Hao2, Zhigang Cheng1, Xu Zhang3, Feng Cao4, Xiaoling Yu1, Zhiyu Han1, Fangyi Liu1, Mengjuan Mu1, Jianping Dou1, Xin Li1, Damian Edward Dupuy5, Jie Yu1, Ping Liang1.   

Abstract

PURPOSE: To retrospectively review long-term oncologic outcomes after ultrasound (US)-guided percutaneous microwave ablation (MWA) of T1a renal cell carcinoma (RCC) and to identify the incidence and risk factors that predict local tumor progression (LTP) after MWA of RCC.
MATERIALS AND METHODS: The present study was approved by the institutional review board. A total of 162 patients with 171 RCC nodules (mean size, 2.6 ± 0.8 cm; range, 0.6-4.0 cm) were treated by MWA between April 2006 and January 2017. The influence of eight factors (age; sex; longest tumor diameter; tumor number, location and pathology type; ablation power and time) affecting the risk of LTP was assessed. Univariate Kaplan-Meier and Cox proportional hazard models were used for statistical analysis.
RESULTS: LTP occurred in five patients (5 tumors) after US-guided percutaneous MWA of stage T1a RCC. The overall occurrence of LTP was 2.9% per tumor and 3.0% per patient with a median follow-up of 45.5 months. Among the 162 patients, there were no instances of LTP-related deaths; however, 20 patients died of other diseases. All patients with LTP survived through follow-up. The survival rate of LTP-free patients at 1, 3 and 5 years were 98.7%, 89.5% and 82.1%, respectively (p = .38). Univariate and multivariate analysis identified tumor location to be the only independent predictor of LTP.
CONCLUSIONS: US-guided percutaneous MWA for T1a RCC achieved a relatively low LTP incidence rate. Tumors adjacent to the renal pelvis or bowel increased the potential of LTP occurrence.

Entities:  

Keywords:  Ultrasound; local tumor progression; microwave ablation; renal cell carcinoma

Mesh:

Year:  2018        PMID: 29807450     DOI: 10.1080/02656736.2018.1475684

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  5 in total

1.  Tumor location does not limit percutaneous treatment of small renal masses with microwave ablation.

Authors:  Xiaosong Meng; Rashed Ghandour; Vitaly Margulis
Journal:  Ann Transl Med       Date:  2019-09

2.  Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma.

Authors:  B M Aarts; W Prevoo; M A J Meier; A Bex; R G H Beets-Tan; E G Klompenhouwer; F M Gómez
Journal:  Cardiovasc Intervent Radiol       Date:  2020-02-12       Impact factor: 2.740

3.  Evaluation of Analgesia Effect after Ultrasound-Guided Laparoscopic Renal Surgery.

Authors:  Xiaolei You; Wei Liu
Journal:  Comput Math Methods Med       Date:  2021-12-24       Impact factor: 2.238

4.  A multicenter 10-year oncologic outcome of ultrasound-guided percutaneous microwave ablation of clinical T1 renal cell carcinoma: will it stand the test of time?

Authors:  Jie Yu; Hui Wang; Zhi-Gang Cheng; Fang-Yi Liu; Qin-Ying Li; Guang-Zhi He; Yan-Chun Luo; Xiao-Ling Yu; Zhi-Yu Han; Ping Liang
Journal:  Eur Radiol       Date:  2021-06-30       Impact factor: 5.315

5.  Long-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center.

Authors:  Giovanni Mauri; Francesco Alessandro Mistretta; Guido Bonomo; Nicola Camisassi; Andrea Conti; Paolo Della Vigna; Matteo Ferro; Stefano Luzzago; Daniele Maiettini; Gennaro Musi; Nicolò Piacentini; Gianluca Maria Varano; Ottavio de Cobelli And Franco Orsi
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.